Haviland Kate 4

What Happened
Kate Haviland, a director of Avalyn Pharma (AVLN), was granted a derivative award covering 26,978 shares on April 29, 2026. The reported acquisition price is $0.00 (total reported value $0), indicating an equity award/option rather than a cash purchase. This is an award (Transaction code A) rather than a market buy or sale.

Key Details

• Transaction date: 2026-04-29; Form 4 filed 2026-05-01 (timely filing).
• Reported amount: 26,978 shares; reported price: $0.00; reported value: $0.
• Shares owned after transaction: not specified in the provided summary of the filing.
• Footnote: 25% of the shares underlying this option vest and become exercisable on September 12, 2025, with the remaining 75% vesting in thirty-six equal monthly installments thereafter, subject to continued service.
• Type: Derivative award/option grant (A). No indication of a cashless exercise or immediate sale.

Context
This was a compensation-style equity award to a director, which vests over time and does not represent an immediate sale or purchase of stock. Such grants are commonly used to align directors’ interests with shareholders, but the award alone does not signal an immediate change in insider buying/selling activity.